The Committee discusses Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) 125387, Aflibercept Solution for intravitreal injection in a virtual meeting to be held on January 9 at 9:30 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- 2seventy Bio announces amendment to collaboration with Regeneron
- CytomX Therapeutics updates business, announces 2023 relationship with Moderna
- Sensei announces clinical supply agreement with Regeneron for Libtayo
- Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
- Opco reveals three biotech stocks that will outperform in 2023